ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Hypogonadism Management and Cardiovascular Health
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 184854" data-attributes="member: 13851"><p><strong>Abstract </strong></p><p></p><p><em><span style="color: rgb(184, 49, 47)">In the early days of its use, testosterone therapy faced skepticism regarding its safety and efficacy. After a converging consensus that testosterone therapy was safe and effective for the treatment of hypogonadism, several recent studies showed adverse cardiovascular outcomes associated with testosterone treatment, ultimately resulting in a mandated FDA label warning about the unknown safety of testosterone therapy. </span><span style="color: rgb(44, 130, 201)"><strong>Given the clear efficacy of testosterone therapy in the treatment of hypogonadism, establishing the safety of this therapeutic tool is essential. This article summarizes the current evidence regarding the cardiovascular safety of testosterone therapy for the management of hypogonadism, as well as the proposed mechanisms that may explain testosterone’s underlying effects.</strong> </span></em></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(44, 130, 201)">*</span></strong><span style="color: rgb(184, 49, 47)"><u><em><strong>Initiated in 2018, the </strong></em></u></span><strong><span style="color: rgb(44, 130, 201)"><em><u>TRAVERSE trial</u></em></span><span style="color: rgb(184, 49, 47)"><em><u> is a very large, randomized, controlled trial that will likely be sufficiently powered to show clear relationships between TTh and cardiovascular events</u>. The trial randomly assigned 6,000 hypogonadal men at high risk of cardiovascular disease who are ages 45-80 to receive either T gel or placebo. <u>The treatment duration is currently set at 5 years</u>. The primary endpoint for the trial is time to MACE, which includes nonfatal MI, nonfatal stroke, or cardiovascular mortality. <u>The </u></em></span><span style="color: rgb(44, 130, 201)"><em><u>TRAVERSE trial </u></em></span></strong><span style="color: rgb(184, 49, 47)"><em><strong><u>will give a more coherent picture of the outcomes associated with TTh</u>.</strong></em></span></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(0, 0, 0)">Conclusion </span></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)"><em>Testosterone is clearly a major player in cardiovascular and metabolic health and physiology. Although some epidemiological data show an increase in adverse cardiovascular events with the provision of T, most studies do not support this suggestion. Most RCTs to date are underpowered and do not provide clear, conclusive evidence to repudiate the small numbers of studies that indicate an increased risk. </em></span><span style="color: rgb(44, 130, 201)"><em><u>To bolster the evidence regarding the safety of TTh, larger clinical trials such as the TRAVERSE trial will provide key insights</u>. <u>Until then, clinicians should be aware of the overall health impacts of hypogonadism and TTh and advise patients with honest communication about the current evidence</u>. </em></span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 184854, member: 13851"] [B]Abstract [/B] [I][COLOR=rgb(184, 49, 47)]In the early days of its use, testosterone therapy faced skepticism regarding its safety and efficacy. After a converging consensus that testosterone therapy was safe and effective for the treatment of hypogonadism, several recent studies showed adverse cardiovascular outcomes associated with testosterone treatment, ultimately resulting in a mandated FDA label warning about the unknown safety of testosterone therapy. [/COLOR][COLOR=rgb(44, 130, 201)][B]Given the clear efficacy of testosterone therapy in the treatment of hypogonadism, establishing the safety of this therapeutic tool is essential. This article summarizes the current evidence regarding the cardiovascular safety of testosterone therapy for the management of hypogonadism, as well as the proposed mechanisms that may explain testosterone’s underlying effects.[/B] [/COLOR][/I] [B][COLOR=rgb(44, 130, 201)]*[/COLOR][/B][COLOR=rgb(184, 49, 47)][U][I][B]Initiated in 2018, the [/B][/I][/U][/COLOR][B][COLOR=rgb(44, 130, 201)][I][U]TRAVERSE trial[/U][/I][/COLOR][COLOR=rgb(184, 49, 47)][I][U] is a very large, randomized, controlled trial that will likely be sufficiently powered to show clear relationships between TTh and cardiovascular events[/U]. The trial randomly assigned 6,000 hypogonadal men at high risk of cardiovascular disease who are ages 45-80 to receive either T gel or placebo. [U]The treatment duration is currently set at 5 years[/U]. The primary endpoint for the trial is time to MACE, which includes nonfatal MI, nonfatal stroke, or cardiovascular mortality. [U]The [/U][/I][/COLOR][COLOR=rgb(44, 130, 201)][I][U]TRAVERSE trial [/U][/I][/COLOR][/B][COLOR=rgb(184, 49, 47)][I][B][U]will give a more coherent picture of the outcomes associated with TTh[/U].[/B][/I][/COLOR] [B][COLOR=rgb(0, 0, 0)]Conclusion [/COLOR] [COLOR=rgb(184, 49, 47)][I]Testosterone is clearly a major player in cardiovascular and metabolic health and physiology. Although some epidemiological data show an increase in adverse cardiovascular events with the provision of T, most studies do not support this suggestion. Most RCTs to date are underpowered and do not provide clear, conclusive evidence to repudiate the small numbers of studies that indicate an increased risk. [/I][/COLOR][COLOR=rgb(44, 130, 201)][I][U]To bolster the evidence regarding the safety of TTh, larger clinical trials such as the TRAVERSE trial will provide key insights[/U]. [U]Until then, clinicians should be aware of the overall health impacts of hypogonadism and TTh and advise patients with honest communication about the current evidence[/U]. [/I][/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Hypogonadism Management and Cardiovascular Health
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top